DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences

DNA Script, a programmable biology company developing next-generation enzymatic DNA synthesis (EDS) technologies, has entered into a distribution agreement with Imperial Life Sciences (ILS) to expand access to the SYNTAX^® platform across India.

Under this agreement, ILS will distribute the SYNTAX platform throughout India from its base in Paris, France, providing local sales, technical support and application expertise to researchers who need faster, more flexible access to high-quality single-stranded DNA (ssDNA) oligonucleotides and decentralized, in-house DNA synthesis.

Expanding decentralized DNA synthesis in a key biotechnology market

The new agreement with Imperial Life Sciences builds on DNA Script’s recent expansion of its global distribution network across Latin America and East Asia, extending the availability of the SYNTAX platform into another key growth market for life sciences research.

By partnering with ILS, DNA Script aims to broaden adoption of decentralized, on-demand DNA synthesis and strengthen access to DNA production capabilities in India’s rapidly growing research ecosystem.

India is one of the world’s fastest-growing biotechnology markets, driving increasing demand for technologies that accelerate research and reduce reliance on overseas supply chains. With more than three decades of experience supporting India’s research community, Imperial Life Sciences offers an established nationwide network that spans academic institutions, biotechnology companies, pharmaceutical organizations and research laboratories.

Addressing DNA supply chain challenges for Indian researchers

Oligonucleotides are essential components of life sciences research, yet many laboratories still depend on external suppliers, leading to delays that can slow scientific progress and extend development timelines. DNA Script’s automated benchtop SYNTAX platform addresses these challenges by enabling researchers to synthesize ssDNA oligonucleotides directly within their laboratories in just a few hours.

By shifting DNA production from centralized manufacturing facilities to the laboratory bench, the SYNTAX platform gives researchers greater control over their workflows, faster turnaround times and reduced dependence on complex supply chains. This decentralized, on-demand approach to DNA synthesis is designed to support a wide range of applications in genomics, synthetic biology and biotechnology across India.

SYNTAX platform capabilities for high-throughput DNA synthesis

The SYNTAX platform combines DNA synthesis, purification and normalization in a single automated workflow. Laboratories can produce up to 384 oligonucleotides in parallel, helping to accelerate design-build-test cycles across diverse research applications.

By integrating enzymatic DNA synthesis technology with automated processing, the SYNTAX platform supports high-quality ssDNA oligonucleotide production directly at the point of use. This capability is particularly valuable for Indian research institutions and biotechnology companies seeking to streamline experimental timelines and reduce logistical complexity.

Marc Montserrat, Chief Executive Officer, DNA Script, commented, “Partnering with Imperial Life Sciences means laboratories across India can now access SYNTAX locally, with the speed, quality and scalability their research demands. Together, we are helping researchers reduce reliance on external DNA supply chains and accelerate scientific discovery through on-demand, in-house DNA synthesis.”

Neeraj Gupta, Director (sales), Imperial Life Sciences, added, “We are excited to partner with DNA Script to bring the SYNTAX platform to researchers across India. This innovative technology empowers scientists to accelerate research by reducing dependency on external oligo supplies and significantly shortening the design-build-test cycle.”

“By combining DNA Script’s enzymatic DNA synthesis technology with our nationwide reach and technical expertise, we look forward to supporting India’s growing genomics, synthetic biology and biotechnology communities with faster and more flexible access to DNA.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>